MDV 3100 Clinical Study

Question of the week:

What’s the latest on the MDV 3100 clinical study? 

What is the mode of action of this oral drug?

 

Video Blog Presentation:

Dr. Celestia Higano will talk about the status of the drug

and info about the Prevail study- MDV 3100 prior to

Chemotherapy.  Includes animation of the mode of  action.

The related article of the week:

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. Epub 2011 Sep 13.  Novel therapies for metastatic castrate-resistant prostate cancerDayyani F, Gallick GE, Logothetis CJ, Corn PG.

This entry was posted in Castration Resistant Prostate Cancer, Hormonal Blockade, Hormone Refractory Disease, Metastatic Disease, Treatments for Prostate Cancer and tagged . Bookmark the permalink.